Overview

• Pfizer will offer Medicaid prices aligned with the lowest charged in comparable wealthy countries and match peer-country launch prices for new drugs.
• The administration plans a TrumpRx portal in 2026 for direct cash purchases, with White House-listed discounts such as Eucrisa at roughly 80% off, Xeljanz about 40% off, and Zavzpret about 50% off.
• Pfizer secured a three-year reprieve from threatened pharmaceutical tariffs and pledged roughly $70 billion for U.S. manufacturing and research.
• Officials say consumers are not expected to see lower prices from the Pfizer deal until 2026, including the rollout of TrumpRx.
• The White House is pursuing similar agreements with other drugmakers, while the impact on Medicare beneficiaries and people with private insurance remains unclear.